ARA-290

cibinetideLyophilized powder

ARA-290 (cibinetide) is an 11-amino-acid peptide engineered from part of erythropoietin (EPO). Its developers designed it to act on what they call the innate repair receptor without stimulating red blood cell production; it has been tested in small Phase 2 trials and is not FDA-approved. Below: today's vial sizes, prices through our link and the vendor's COA details.

Size

$3.00/mg · In stock

Price

$30.00

List

$60.00

Buy 10 mg at Ascension Peptides

Price shown includes the 50% discount Ascension Peptides applies through our link.

Volume pricing at Ascension Peptides

3+ vials3% offin cart
5+ vials5% offin cart
10+ vials10% offin cart

Applied in Ascension Peptides's cart; how it combines with our discount is set at checkout.

Sold by Ascension Peptides. The Peptide Catalog does not sell peptides; we earn a commission if you buy through this link, at no extra cost to you. For laboratory research use only, not for human or veterinary use. Not FDA-approved. Nothing on this page is medical or dosing advice.

ARA-290Ascension Peptides

Third-party testedResearch use only

Certificate of AnalysisVendor-stated: Third-party tested · HPLC · public COAView

Vendor-stated testing: Third-party tested · HPLC · public COA
Listed on our ara-290 vendor comparison, ordered by our vendor rankings
Lyophilized powder · laboratory research use only

Research-context information only. ARA-290 is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.

Vial sizes listed by the vendor

ARA-290 Vial Sizes & Prices

ARA-290 vial sizes, prices and lots at Ascension Peptides
Size	List	Price	Per mg	Availability
10 mg	$60.00	$30.00	$3.00	In stock

Prices checked today, 5:03 AM CT on Ascension Peptides's site. Vendor-stated testing: Third-party tested · HPLC · public COA. The lot certificate is on Ascension Peptides's product page. Sizes not re-checked in the last 7 days are hidden. The vendor's checkout is final.

Test results

ARA-290 Certificate of Analysis

Ascension Peptides publishes its certificates publicly (vendor-stated: Third-party tested · HPLC · public COA). Match the lot number on the vial to its certificate.

View the ARA-290 certificate on Ascension Peptides's product page.

How to check one: how to verify a peptide COA.

ARA-290 Dosing in Clinical Research

Neuropathic Pain / Nerve Repair / Anti-Inflammatory

Educational reference only. Individual responses vary. Consult healthcare provider before use.

Vial Size

10 mg

Reconstitution

1 ml BAC water (10 mg/ml)

Dose

4 mg (40 units on 1ml syringe)

Timing

Frequency

Once daily

Duration

28-day courses reported in trials

Protocol Notes

EPO-derived innate repair receptor agonist. Phase 2 sarcoidosis and type 2 diabetes trials used 4 mg/day subcutaneous for 28 days. Does not stimulate red blood cell production.

Why This Dosing Protocol

Why 4 mg daily? Phase 2 trials in both sarcoidosis and type 2 diabetes used 4 mg subcutaneous once daily. A dose-ranging study comparing 1 mg, 4 mg, and 8 mg reported the 4 mg dose produced the strongest increase in corneal nerve fiber area.

Why 28-day courses? The published trials administered ARA 290 daily for 28 days, with measured nerve and symptom changes assessed over that window and follow-up. These are documented trial protocols, not dosing recommendations.

Full Dosing Guide Reconstitution Calculator Cycle Cost Calculator

How ARA-290 Works

Innate Repair Receptor Agonist — EPO-Derived Tissue-Protective Peptide

Target → Signal → Effect → Outcomes

Target

Innate Repair Receptor (EPOR / Beta-Common Heterocomplex)

ARA-290 (cibinetide) is an 11-amino-acid peptide corresponding to the helix-B face of erythropoietin. It selectively binds the innate repair receptor — a heterocomplex of the EPO receptor and the beta-common receptor (CD131) — which is upregulated in injured and inflamed tissue. It does not activate the classic homodimeric EPO receptor that drives red blood cell production.

Cellular Signal

Anti-Inflammatory + Anti-Apoptotic Signaling

Innate repair receptor activation triggers tissue-protective signaling cascades that dampen local inflammation, reduce cell death (apoptosis), and support repair processes. In neuropathic models, published research describes reduced spinal microglial activation and inflammatory signaling.

Systemic Effect

Nerve Fiber Repair + Inflammation Resolution

Phase 2 trials documented regrowth of small nerve fibers (measured by corneal confocal microscopy and skin biopsy) and reductions in neuropathic pain. A type 2 diabetes trial also reported improvements in HbA1c and lipid markers, all without raising hematocrit.

What You Notice

Reduced Neuropathic Pain → Improved Function

Trial subjects reported reduced neuropathic pain and improved physical functioning over 28-day courses, with some effects sustained through 16 weeks of follow-up. This reports what trials documented, not what should be expected for any individual.

What Makes This Peptide Different

ARA-290 was engineered by Brines and Cerami to separate erythropoietin's tissue-protective signaling from its red-blood-cell-stimulating and clotting effects. Standard EPO carries thrombotic and hypertensive risk; ARA-290 activates only the innate repair receptor, so published trials reported no significant change in hematocrit. It holds FDA Orphan Drug and Fast Track designations for sarcoidosis-associated neuropathic pain.

Technical specifications

ARA-290 chemical & analytical data

Also known as: cibinetide
Form: Lyophilized (freeze-dried) powder in a sealed vial
Presentation: 10 mg
Regulatory status: Investigational (Phase 2). Not FDA-approved for any use.

ARA-290 Reconstitution Calculator

Dilution math and unit conversions. Prefilled using a common vial size for this peptide.

Open calculator

Storage & Handling

Storage at a glance

Proper storage temperatures, shelf life, reconstitution best practices, and travel tips for lyophilized and reconstituted peptides.

Powder: Freezer

1+ year at -20°C

Reconstituted: Fridge

4 weeks max at 2-8°C

View Complete Storage Guide

Handling specifics

Educational overview on storage, labeling, and traceability considerations for lab environments. Consult primary literature and vendor documentation for specifics.

Powder storage (very stable)

Freezer (-20°C): 1+ year
Refrigerator (2-8°C): 1-3 months
Room temperature: 2-3 weeks (emergency only)

Reconstituted storage (fragile)

MUST refrigerate at 2-8°C
4-week maximum shelf life
NEVER freeze after reconstitution
Use bacteriostatic water for multi-dose

8 answers

ARA-290 FAQ: Buying, COA, Storage & Research

What is ARA-290?

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from the helix-B domain of erythropoietin (EPO). It selectively activates the innate repair receptor — a heterocomplex of the EPO receptor and the beta-common receptor (CD131) — to trigger anti-inflammatory and tissue-protective signaling without stimulating red blood cell production. It has been studied in Phase 2 trials for sarcoidosis-associated small fiber neuropathy and diabetic neuropathy.

What doses did ARA-290 trials use?

Phase 2 trials in sarcoidosis and type 2 diabetes administered 4 mg subcutaneously once daily for 28 days. A dose-ranging sarcoidosis study compared 1 mg, 4 mg, and 8 mg daily and reported the 4 mg dose produced the strongest increase in corneal nerve fiber area. These are documented trial protocols, not dosing recommendations.

What did ARA-290 trials report for neuropathic pain?

A 2013 Molecular Medicine trial (Dahan et al.) reported that 28 days of daily ARA 290 reduced neuropathic symptoms and increased corneal small nerve fiber density in sarcoidosis patients, with improvement sustained through 16 weeks of follow-up. A 2017 dose-ranging study (Culver et al.) reported clinically meaningful pain reductions in subjects with moderate-to-severe baseline pain, strongest in the 4 mg group.

Does ARA-290 raise red blood cell count like EPO?

No. ARA-290 was engineered to separate EPO's tissue-protective signaling from its erythropoietic (red-blood-cell-stimulating) and thrombotic effects. Published trials reported no significant change in hematocrit and an excellent safety profile across the doses studied.

What adverse events did ARA-290 trials report?

Across the Phase 2 sarcoidosis and diabetes trials, investigators reported no significant safety issues for any treatment group. The most commonly noted events were mild injection-site reactions. ARA-290 holds FDA Orphan Drug and Fast Track designations for sarcoidosis-associated neuropathic pain but is not an approved medication.

How long does reconstituted peptide last?

Once mixed with bacteriostatic water, peptides remain stable for up to 4 weeks when refrigerated at 2-8°C (36-46°F). Unopened powder can last 1+ year in the freezer. Get our complete Storage & Travel Guide.

Is this peptide legal to purchase?

Peptides sold "for research purposes only" are legal to purchase in the US, but are not FDA-approved for human use outside of specific medical applications. Always consult a healthcare provider before use.

New to peptides?

Take our Peptide Match tool to find the best peptide for your goals. You can also read our Complete Guide to Peptides to learn the basics.

ARA-290 Research Articles

guides

Compare ARA-290 Vendors Before You Buy

Disclosure: we may earn affiliate commission from qualifying purchases. Educational information only — not medical advice.

ARA-290

ARA-290 Vial Sizes & Prices

ARA-290 Certificate of Analysis